Osteoarthritis, Knee
Conditions
Brief summary
Present research focuses on the potential of exosomes, which are small vesicles secreted by mesenchymal stem cells (MSCs), as a therapeutic approach for osteoarthritis (OA). OA is a degenerative joint disorder characterized by the destruction of cartilage and loss of extracellular matrix. It's associated with pro-inflammatory cytokines and increased expression of matrix metalloproteinase (MMP) and a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS). MSCs have been explored as a new treatment for OA over the last decade1. It's suggested that the paracrine secretion of trophic factors, in which exosomes play a crucial role, contributes to the mechanism of MSC-based treatment of OA. Exosomes derived from MSCs may suppress OA development. They carry bioactive molecules of the parental cells, including non-coding RNAs (ncRNAs) and proteins and anti-inflammatory factors. These exosomes have shown a significant impact on the modulation of various physiological behaviors of cells in the joint cavity. This research provides hope for developing more effective and predictable methods of using MSC-derived exosomes for OA treatment.
Interventions
BIOLOGICALExosome
intra-articular injection is suggested for two times: day 1and day 90
Sponsors
Isfahan University of Medical Sciences
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
45 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Chronic history (for at least 3 months) of knee joint pain * Body mass index (BMI) between 21.5 and 29.5 * Radiographically documented knee osteoarthritis of grades 1 to 3 (Kellgren-Lawrence (K-L) radiographic classification scale)
Exclusion criteria
* Rheumatoid arthritis and other rheumatic diseases * Varus or valgus more than 10 degrees; lateral subluxation of the patella * Deformity at the joint levels or adjacent to the knee due to fracture or any other injury * Complete rupture of the ligament and meniscus leading to laxity or locking * Serious systemic, oncohematological, autoimmune diseases; history of severe allergy; serious failure of vital organs, inability to walk * Hyaluronic acid infiltration within the previous six months * Hemoglobin levels \<10 g/dL;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Western Ontario and McMaster University Osteoarthritis index (WOMAC) | 1, 3, and 6 months. The second injection is repeated in day 90 after first injection. | Filling out the WOMAC questionnaire, evaluating the measures related to knee function |
Countries
Iran
Contacts
Primary ContactLeila Dehghani, Dr
Backup ContactMasoud Soleimani, Prof
Outcome results
None listed